


Raf inhibitor 1 dihydrochloride

| | |
|--------------------|---|
| Cat. No.: | HY-14177A |
| CAS No.: | 1191385-19-9 |
| Molecular Formula: | C ₂₆ H ₂₁ Cl ₃ N ₈ |
| Molecular Weight: | 551.86 |
| Target: | Raf |
| Pathway: | MAPK/ERK Pathway |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | | | |
|-------------------------------------|---|--|-----------------------------------|
| Description | B-Raf inhibitor 1 dihydrochloride is a potent Raf kinase inhibitor with K _i s of 1 nM, 1 nM, and 0.3 nM for B-Raf ^{WT} , B-Raf ^{V600E} , and C-Raf, respectively. | | |
| IC₅₀ & Target | B-Raf 1 nM (K _i) | B-Raf ^{V600E} 1 nM (K _i) | c-Raf 0.3 nM (K _i) |
| In Vitro | B-Raf inhibitor 1 (Compound 13) inhibits A375 and HCT-116 proliferation with IC ₅₀ s of 0.31 and 0.72 μM, respectively. B-Raf inhibitor 1 (Compound 13) binds to and stabilizes B-Raf in a DFG-out, inactive conformation in which the ATP pocket is partially filled by Phe595 and Gly596 from the DFG motif. B-Raf inhibitor 1 (Compound 13) additionally exhibits low micromolar inhibition against wild type B-Raf cell lines, which may be due to off-target kinase activities or alternatively to pan-Raf inhibition, including Raf dimers ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | | |

CUSTOMER VALIDATION

- J Med Chem. 2015 Jan 8;58(1):466-79.
- Patent. US20200147090A1
- Patent. WO2017154001A1.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Wang X, et al. Conformation-specific effects of Raf kinase inhibitors. J Med Chem. 2012 Sep 13;55(17):7332-41.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA